ABERDEEN, Scotland and Singapore, 20th July, 2018 – TauRx Therapeutics Ltd has announced that it has revised the design of its LUCIDITY clinical study (Study TRx-237-039) in light of new guidance issued by the FDA (“Early Alzheimer’s Disease: Developing Drugs for Treatment”) and the European Medicines Agency (“Guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease”) in February 2018. Both guidance documents recognise the importance of treating early stages of Alzheimer’s disease (AD) and offer a clearer regulatory framework for conducting trials in Early AD.
Read more here.
LUCIDITY Study – Protocol Amendment
TauRx Therapeutics Ltd has announced that it has revised the design of its LUCIDITY clinical study (Study TRx-237-039)
